Breaking News Instant updates and real-time market news.

SGMO

Sangamo

$10.80

0.8 (8.00%)

, BMRN

BioMarin

$93.51

0.43 (0.46%)

06:49
11/14/18
11/14
06:49
11/14/18
06:49

JPMorgan downgrades Sangamo to Neutral on 'growing skepticism'

JPMorgan analyst Eric Joseph downgraded Sangamo Therapeutics (SGMO) to Neutral from Overweight and lowered his price target for the shares to $11 from $35. Following the company's Q3 results, the analyst has "growing skepticism" about its lead development programs and "their potential for value creation over the foreseeable future." Visibility into the initial efficacy of the SB-525 / Hemophilia A program "continues to elude, now with indefinite timelines," Joseph tells investors in a research note. With relatively slower recruitment to date, the analyst struggles to see how SB-525 closes ground with the two later-stage competitor FVIII gene therapy programs from BioMarin (BMRN) and Spark Therapeutics (ONCE).

SGMO

Sangamo

$10.80

0.8 (8.00%)

BMRN

BioMarin

$93.51

0.43 (0.46%)

ONCE

Spark Therapeutics

$42.74

1.12 (2.69%)

  • 14

    Nov

SGMO Sangamo
$10.80

0.8 (8.00%)

11/14/18
JPMS
11/14/18
DOWNGRADE
Target $11
JPMS
Neutral
Sangamo downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Eric Joseph downgraded Sangamo Therapeutics to Neutral and lowered his price target for the shares to $11 from $35. The analyst sees a lack of catalysts following last week's Q3 results.
11/09/18
11/09/18
DOWNGRADE

Neutral
Sangamo downgraded to Neutral after Hemophilia A 'about-face' at Guggenheim
As previously reported, Guggenheim analyst Whitney Ijem downgraded Sangamo to Neutral from Buy after the company reported Q3 earnings and announced that it will not present initial SB-525 in hemophilia A data at ASH in December. The company's "about-face" on the SB-525 data disclosure is concerning and makes Ijem question the timelines around additional updates, she tells investors. While she understand the company's desire to wait for a "complete clinical picture" before announcing data, she worries that it might be a moving target for hemophilia A and potentially other programs, Ijem added. She withdrew her prior $18 price target on Sangamo as she awaits more clarity on what can be expected from the company in 2019.
11/09/18
GUGG
11/09/18
DOWNGRADE
GUGG
Neutral
Sangamo downgraded to Neutral from Buy at Guggenheim
10/09/18
GUGG
10/09/18
INITIATION
GUGG
Buy
Sangamo initiated with a Buy at Guggenheim
Guggenheim analyst Whitney Ijem initiated Sangamo with a Buy rating and $18 price target, citing the company's diversified tech platform, pipeline, progress on partnerships, and the new TxCell acquisition.
BMRN BioMarin
$93.51

0.43 (0.46%)

10/15/18
PIPR
10/15/18
NO CHANGE
PIPR
Piper lists names to own in Biopharma after recent selloff
Piper Jaffray's biopharma analyst team highlighted names to own in the Biopharma sector following the recent selloff of the broader market. The firm's ideas include: Adamas Pharmaceuticals (ADMS), Agios Pharmaceuticals (AGIO), Agios Pharmaceuticals (ALNY), Alexion (ALXN), Bluebird Bio (BLUE), BioMarin (BMRN), CymaBay (CBAY), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), Jazz Pharmaceuticals (JAZZ), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and Xencor (XNCR).
10/23/18
ADAM
10/23/18
NO CHANGE
Target $116
ADAM
Buy
BioMarin price target raised to $116 from $113 at Canaccord
Canaccord analyst Michelle Gilson raised her price target on BioMarin to $116 from $113 to reflect the talazoparib milestone and stronger Palynziq launch. She also believes the ValRox study in hemophilia A is still underappreciated and she sees an accelerated filing in the second half of 2019. Gilson reiterated her Buy rating on BioMarin shares.
10/26/18
JEFF
10/26/18
NO CHANGE
Target $125
JEFF
Buy
BioMarin risk/reward favorable into clinical catalysts, says Jefferies
Jefferies analyst Eun Yang keeps a Buy rating on BioMarin with a $125 price target following the company's Q3 results. With currently marketed products providing a $90 per share valuation floor, the risk/reward for BioMarin shares is favorable into multiple clinical catalysts in 2019-2020, which support potential regulatory approval of three new products, Yang tells investors in a post-earnings research note. She points out that BioMarin beat on Q3 product sales and non-GAAP net income while maintains its fiscal 2018 guidance.
10/16/18
JEFF
10/16/18
NO CHANGE
Target $125
JEFF
Buy
BioMarin price target raised to $125 from $118 at Jefferies
Jefferies analyst Eun Yang raised her price target for BioMarin to $125 saying that with multiple clinical catalysts in 2019-2020 supporting potential regulatory approval of three new products, she expects the stock to move higher. If pivotal trials for the three new products, valrox in hemophilia A gene therapy, vosoritide in achondroplasia, and BMN-250 in Sanfilippo B syndrome, are successful, the analyst sees a fair value for BioMarin at $140 per share. The stock's current risk/reward is favorable, particularly with currently marketed products providing a $90 per share "valuation floor," Yang tells investors in a research note. She keeps a Buy rating on BioMarin.
ONCE Spark Therapeutics
$42.74

1.12 (2.69%)

11/07/18
CHDN
11/07/18
NO CHANGE
Target $70
CHDN
Buy
uniQure price target raised to $70 from $50 at Chardan
Chardan analyst Gbola Amusa increased his price target on uniQure (QURE) to $70 from $50, stating that he believes the market is missing important dynamics in uniQure's favor over hemB competition from Pfizer (PFE) and Spark Therapeutics (ONCE). Amusa said uniQure's manufacturing is "much more scalable" than Pfizer's and he also believes uniQure's IP may cover the construct utilized by Pfizer. Amusa keeps a Buy rating on uniQure shares.
11/07/18
BMOC
11/07/18
NO CHANGE
Target $48
BMOC
Market Perform
Spark Therapeutics price target lowered to $48 from $60 at BMO Capital
BMO Capital analyst Matthew Luchini lowered his price target on Spark Therapeutics to $48 after its Q3 earnings miss, stating that the weakness in its shares also reflects continued uncertainty on the outlook for SPK-8011 for hemophilia A. The analyst also points to the company's "lack of catalysts", stating that the announcement that "FVIII levels from key highest dose cohort will not be available until MY19, rather than at ASH, pushes out a key dataset that could potentially get the program back on track". With Spark Therapeutics' Luxturna results also suggesting "slow but steady growth", Luchini keeps his Market Perform rating on the stock based on its limited near-term upside.
11/07/18
11/07/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Target (TGT) upgraded to Outperform from Market Perform at Cowen with analyst Oliver Chen saying he believes its combination of strong price value, convenient digitally-enabled pick up options, private brand innovation, and traffic will drive the stock higher. 2. Spark Therapeutics (ONCE) upgraded to Strong Buy from Outperform at Raymond James, to Buy from Neutral at B. Riley FBR, and to Neutral from Underperform at Wedbush. 3. USA Compression (USAC) upgraded to Outperform from Sector Perform at RBC Capital with analyst TJ Schultz saying the company's strong market fundamentals and synergies from its CDM compression acquisition should allow it to de-lever and grow coverage. 4. Noble Energy (NBL) upgraded to Outperform from Market Perform at Raymond James and to Buy from Hold at Tudor Pickering. 5. QEP Resources (QEP) upgraded to Buy from Hold at Tudor Pickering. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/07/18
RAJA
11/07/18
UPGRADE
Target $72
RAJA
Strong Buy
Spark Therapeutics upgraded to Strong Buy at Raymond James
As previously reported, Raymond James upgraded Spark Therapeutics to Strong Buy from Outperform and reduced its price target to $72 from $82. Analyst Reni Benjamin said shares are trading at a 12-month low at a time when his confidence in the Hem A program has increased, and the clinical pipeline is expanding and will soon include Pompe disease as well as a novel asset to tackle Hem A patients with Factor VIII inhibitors.

TODAY'S FREE FLY STORIES

HRL

Hormel Foods

$40.93

0.04 (0.10%)

, BJ

BJ's Wholesale

$22.41

0.785 (3.63%)

14:57
08/21/19
08/21
14:57
08/21/19
14:57
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

HRL

Hormel Foods

$40.93

0.04 (0.10%)

BJ

BJ's Wholesale

$22.41

0.785 (3.63%)

DKS

Dick's Sporting

$32.73

0.375 (1.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 15

    Sep

  • 24

    Sep

  • 01

    Oct

SNPS

Synopsys

$131.58

1.55 (1.19%)

, SPLK

Splunk

$128.44

1.8 (1.42%)

14:56
08/21/19
08/21
14:56
08/21/19
14:56
Earnings
Notable companies reporting after market close »

Notable companies…

SNPS

Synopsys

$131.58

1.55 (1.19%)

SPLK

Splunk

$128.44

1.8 (1.42%)

KEYS

Keysight Technologies

$88.52

1.23 (1.41%)

ZAYO

Zayo Group

$33.79

-0.01 (-0.03%)

JWN

Nordstrom

$26.29

1.16 (4.62%)

PSTG

Pure Storage

$13.81

0.14 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 21

    Aug

  • 21

    Aug

  • 21

    Aug

  • 21

    Aug

  • 28

    Aug

  • 28

    Aug

  • 04

    Sep

  • 09

    Sep

  • 10

    Sep

  • 23

    Sep

  • 26

    Sep

  • 27

    Sep

  • 10

    Oct

  • 15

    Oct

  • 12

    Dec

  • 16

    Dec

AKTS

Akoustis

$6.70

0.21 (3.24%)

14:54
08/21/19
08/21
14:54
08/21/19
14:54
Conference/Events
Akoustis Technologies to hold a business news update conference call »

Business News Update…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 12

    Sep

  • 17

    Sep

  • 18

    Sep

BREW

Craft Brew

$12.69

-0.07 (-0.55%)

, BUD

AB InBev

$95.87

0.87 (0.92%)

14:52
08/21/19
08/21
14:52
08/21/19
14:52
On The Fly
Before the Move: Watch Craft Brew ahead of AB InBev offer deadline »

According to their 2016…

BREW

Craft Brew

$12.69

-0.07 (-0.55%)

BUD

AB InBev

$95.87

0.87 (0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 25

    Oct

  • 12

    Nov

JWN

Nordstrom

$26.29

1.16 (4.62%)

14:49
08/21/19
08/21
14:49
08/21/19
14:49
Options
Nordstrom options imply 18.9% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

SPY

SPDR S&P 500 ETF Trust

$292.44

2.41 (0.83%)

, SPX

S&P 500

$0.00

(0.00%)

14:46
08/21/19
08/21
14:46
08/21/19
14:46
General News
Fed minutes show July rate cut to help keep growth, insure against low inflation »

According to the minutes…

SPY

SPDR S&P 500 ETF Trust

$292.44

2.41 (0.83%)

SPX

S&P 500

$0.00

(0.00%)

SMH

Market Vectors Semiconductor

$114.59

1.16 (1.02%)

IWM

iShares Trust Russell 2000 Index Fund

$150.37

1.255 (0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXL

American Axle

$6.75

0.1 (1.50%)

14:45
08/21/19
08/21
14:45
08/21/19
14:45
Options
American Axle call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GILD

Gilead

$63.93

0.47 (0.74%)

14:41
08/21/19
08/21
14:41
08/21/19
14:41
Hot Stocks
Gilead says submitted petitions to USPTO requesting review of HHS patents »

Gilead announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

14:40
08/21/19
08/21
14:40
08/21/19
14:40
General news
Treasury Action: there was scant movement in the markets »

Treasury Action: there…

AEP

American Electric

$91.13

0.38 (0.42%)

14:36
08/21/19
08/21
14:36
08/21/19
14:36
Hot Stocks
American Electric seeks proposals for several coal types »

American Electric Power…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

APU

AmeriGas

$31.21

-0.82 (-2.56%)

, UGI

UGI Corporation

$48.95

0.45 (0.93%)

14:32
08/21/19
08/21
14:32
08/21/19
14:32
Hot Stocks
AmeriGas unitholders approve merger with UGI Corporation »

UGI Corporation (UGI) and…

APU

AmeriGas

$31.21

-0.82 (-2.56%)

UGI

UGI Corporation

$48.95

0.45 (0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,192.55

9.12 (0.77%)

, GOOGL

Alphabet Class A

$1,193.00

8.74 (0.74%)

14:31
08/21/19
08/21
14:31
08/21/19
14:31
Periodicals
Google DeepMind's Suleyman placed on leave, Bloomberg reports »

Mustafa Suleyman,…

GOOG

Alphabet

$1,192.55

9.12 (0.77%)

GOOGL

Alphabet Class A

$1,193.00

8.74 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Oct

OIH

Oil Services Holders Trust

$11.64

0.04 (0.34%)

14:30
08/21/19
08/21
14:30
08/21/19
14:30
Options
Delta neutral put sale in Oil Services ETF appears to take gains »

Delta neutral put sale in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JMIA

Jumia Technologies

$12.54

-2.15 (-14.64%)

14:18
08/21/19
08/21
14:18
08/21/19
14:18
On The Fly
Citron target Jumia plunges as improper orders on platform put under review »

Shares of Jumia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
08/21/19
08/21
14:17
08/21/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
08/21/19
08/21
14:16
08/21/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:15
08/21/19
08/21
14:15
08/21/19
14:15
General news
FOMC minutes didn't provide strong clues on the direction of rates »

FOMC minutes didn't…

14:15
08/21/19
08/21
14:15
08/21/19
14:15
General news
FX Action: The dollar »

FX Action: The dollar…

WYND

Wyndham Destinations

$42.79

0.21 (0.49%)

14:11
08/21/19
08/21
14:11
08/21/19
14:11
Hot Stocks
Wyndham Destinations to add 140 jobs in Orlando expansion »

Wyndham Destinations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

SPY

SPDR S&P 500 ETF Trust

$292.47

2.44 (0.84%)

, SPX

S&P 500

$0.00

(0.00%)

14:04
08/21/19
08/21
14:04
08/21/19
14:04
General news
Fed minutes show 'couple of participants' would have preferred 50 bps rate cut »

The minutes for the…

SPY

SPDR S&P 500 ETF Trust

$292.47

2.44 (0.84%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Symbol is now VWAGY

$0.00

(0.00%)

, POAHY

Porsche

$0.00

(0.00%)

14:03
08/21/19
08/21
14:03
08/21/19
14:03
Hot Stocks
Porsche acquires minority stake in Israeli startup TriEye »

Volkswagen's (VLKAY)…

VLKAY

Symbol is now VWAGY

$0.00

(0.00%)

POAHY

Porsche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$292.42

2.39 (0.82%)

, SPX

S&P 500

$0.00

(0.00%)

14:02
08/21/19
08/21
14:02
08/21/19
14:02
General news
Fed minutes show July rate cut viewed by 'most' on FOMC as 'recalibration' »

The minutes for the…

SPY

SPDR S&P 500 ETF Trust

$292.42

2.39 (0.82%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$35.06

0.44 (1.27%)

14:01
08/21/19
08/21
14:01
08/21/19
14:01
Hot Stocks
Pfizer says FDA grants XTANDI application priority review »

Astellas Pharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 16

    Sep

TGT

Target

$102.13

16.555 (19.35%)

13:52
08/21/19
08/21
13:52
08/21/19
13:52
Recommendations
Target analyst commentary at Baird »

Target price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

JMIA

Jumia Technologies

$12.43

-2.26 (-15.38%)

13:47
08/21/19
08/21
13:47
08/21/19
13:47
Recommendations
Jumia Technologies analyst commentary at Stifel »

Jumia's report…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.